1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone | 304854-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone
• 英文别名: 1-(4Amino-3'-chloro-biphenyl-3-yl)-ethanone；1-[2-amino-5-(3-chlorophenyl)phenyl]ethanone
• CAS: 304854-19-1
• 化学式: C₁₄H₁₂ClNO
• 分子量: 245.708
• InChiKey: WTWHARNMMYPRFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone 、 1-丙炔溴化镁 在 CDI 作用下， 生成 6-(3-Chlorophenyl)-4-methyl-4-propyn-1-yl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
  参考文献：
  名称：

  Combination regimens using progesterone receptor modulators

  摘要：

  这项发明涉及利用替代吲哚啉衍生物化合物的循环组合疗法和方案，这些化合物是孕激素受体拮抗剂，具有以下一般结构： 其中R1和R2可以是单个取代基或融合形成螺环或杂环螺环；R3为H、OH、NH2、C1至C6烷基、取代的C1至C6烯丙基、C3至C6烯基、取代的C1至C6烯基、炔基或取代的炔基、CORC；RC为H、C1至C3烷基、取代的C1至C3烷基、芳基、取代的芳基、C1至C3烷氧基、取代的C1至C3烷氧基、C1至C3氨基烷基、或取代的C1至C3氨基烷基；R4为H、卤素、CN、NO2、C1至C6烷基、取代的C1至C6烷基炔基、或取代的炔基、C1至C6烷氧基、取代的C1至C6烷氧基、氨基、C1至C6氨基烷基、或取代的C1至C6氨基烷基；R5从包含O、S、SO、SO2或NR6的1、2或3个杂原子的五元或六元环的三取代苯环中选择，并含有来自包括H、卤素、CN、NO2、氨基和C1至C3烷基、C1至C3烷氧基、C1至C3氨基烷基、CORF或NRGCORF的一个或两个独立取代基；或其药学上可接受的盐。这些治疗方法可用于避孕或用于治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症；多囊卵巢综合征、子宫内膜、卵巢、乳腺、结肠、前列腺的癌瘤和腺癌，或减轻副作用或循环性月经出血。该发明的其他用途包括促进食物摄入。

  公开号：

  US06444668B1
• 作为产物：
  描述：

  2-amino-5-(3-chlorophenyl)-N-methoxy-N-methylbenzamide 在 甲基锂 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 0.5h， 以47%的产率得到1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone
  参考文献：
  名称：

  Quinazolinone and benzoxazine derivatives as progesterone receptor modulators

  摘要：

  这项发明提供了具有以下一般结构的孕激素受体激动剂和拮抗剂的化合物：其中：R1和R2分别选择自H、CORA或NRBCORA，或者可选择取代的烷基、烯基、炔基、环烷基、芳基或杂环基；或者R1和R2融合形成：3到8成员的螺环烷基、烯基或杂环环；RA为H或可选择取代的烷基、芳基、烷氧基或氨基烷基；RB为H、C1至C3烷基或取代的C1至C3烷基；R3为H、OH、NH2、CORC或可选择取代的烷基、烯基或炔基；RC为H或可选择取代的烷基、芳基、烷氧基或氨基烷基；R4为H、卤素、CN、NO2或可选择取代的烷基、炔基、烷氧基、氨基或氨基烷基；R5为可选择取代的苯或含有1、2或3个来自O、S、SO、SO2或NR6的杂原子的五元或六元环；R6为H或C1至C3烷基；G1为O、NR7或CR7R8；G2为CO、CS或CR7R8；条件是当G1为O时，G2为CR7R8，且G1和G2不能同时为CR7R8；R7和R8为H或可选择取代的烷基、芳基或杂环基；或其药用盐，以及在哺乳动物中使用这些化合物作为孕激素受体激动剂或拮抗剂的方法。

  公开号：

  US06358948B1

文献信息

• Cyclocarbamate derivatives as progesterone receptor modulators
  申请人：——

  公开号：US20020049204A1

  公开（公告）日：2002-04-25

  This invention provides compounds of Formula (I): 1 wherein R 1 and R 2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R 3 is H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, substituted C 1 to C 6 alkenyl, alkynyl, or substituted alkynyl, COR C ; R C is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl; R 4 is H, halogen, CN, NO 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, alkynyl, or substituted alkynyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, amino, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl; and R 5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO 2 or NR 6 and containing one or two independent substituents from the group including H, halogen, CN, NO 2 , amino, and C 1 to C 3 alky, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR F , or NR G COR F ; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

  这项发明提供了Formula (I)的化合物： 其中R1和R2可以是单个取代基或融合形成螺环或杂环螺环；R3为H、OH、NH2、C1到C6烷基、取代的C1到C6烷基、C3到C6烯基、取代的C1到C6烯基、炔基或取代的炔基、CORC；RC为H、C1到C3烷基、取代的C1到C3烷基、芳基、取代的芳基、C1到C3烷氧基、取代的C1到C3烷氧基、C1到C3氨基烷基或取代的C1到C3氨基烷基； R4为H、卤素、CN、NO2、C1到C6烷基、取代的C1到C6烷基、炔基或取代的炔基、C1到C6烷氧基、取代的C1到C6烷氧基、氨基、C1到C6氨基烷基或取代的C1到C6氨基烷基；R5从包括O、S、SO、SO2或NR6的1、2或3个杂原子的五元或六元环的三取代苯环中选择，并含有来自包括H、卤素、CN、NO2、氨基和C1到C3烷基、C1到C3烷氧基、C1到C3氨基烷基、CORF或NRGCORF的一个或两个独立取代基；或其药学上可接受的盐，以及将这些化合物用作孕激素受体拮抗剂的药物组合物和方法。
• Cyclothiocarbamate derivatives as progesterone receptor modulators
  申请人：Wyeth

  公开号：US06436929B1

  公开（公告）日：2002-08-20

  The present invention provides compounds which are agonists of the progesterone receptor and have the structures: wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORA or NRBCORA; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; RA is selected from H, amino, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; RC is selected from H or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; Q1 is S, NR7, or CR8R9; R5 is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO2 or NR6; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

  本发明提供了激素受体激动剂化合物，其结构为： 其中R1和R2是独立的取代基，选自H、可选择取代的C1到C6烷基、烯基、炔基或炔基基团、C3到C8环烷基、芳基、取代芳基或杂环基，或CORA或NRBCORA；或者R1和R2融合形成可选择取代的3到8成员螺环烷基或烯基环或含有O、S和N中的一到三个杂原子的螺环环；RA选自H、氨基或可选择取代的C1到C3烷基、芳基、C1到C3烷氧基或C1到C3氨基烷基；RB为H、C1到C3烷基或取代的C1到C3烷基；R3为H、OH、NH2、CORC或可选择取代的C1到C6烷基、C3到C6烯基或炔基基团；RC选自H或可选择取代的C1到C3烷基、芳基、C1到C3烷氧基或C1到C3氨基烷基；Q1为S、NR7或CR8R9；R5为可选择三取代苯环或可选择取代的含有1、2或3个环杂原子（选自O、S、SO、SO2或NR6）的五元或六元杂环环；或其药学上可接受的盐，以及使用这些化合物进行避孕和治疗激素相关疾病的方法。
• [EN] CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS<br/>[FR] DERIVES DE CYCLOTHIOCARBAMATE TENANT LIEU DE MODULATEURS DU RECEPTEUR DE PROGESTERONE
  申请人：AMERICAN HOME PROD

  公开号：WO2000066570A1

  公开（公告）日：2000-11-09

  The present invention provides compounds which are agonists of the progesterone receptor and have structures (I) or (II) wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR?A or NRBCORA; or R1 and R2¿ are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; RA is selected from H, amino, or optionally substituted C¿1? to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; R?B¿ is H, C¿1? to C3 alkyl, or substituted C1 to C3 alkyl; R?3¿ is H, OH, NH¿2 COR?C, or optionally substituted C¿1? to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; R?C¿ is selected from H or optionally substituted C¿1? to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; Q?1¿ is S, NR?7; or CR8R9, R5¿ is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO¿2? or NR?6¿; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

  本发明提供了具有结构（I）或（II）的孕激素受体激动剂化合物，其中R1和R2是独立的取代基，选自H，可选取代的C1至C6烷基，烯基，炔基或C3至C8环烷基，芳基，取代芳基或杂环基，或COR？A或NRBCORA; 或R1和R2¿融合形成可选取代的3至8环螺环烷基或烯基环或含有1至3个杂原子（选自O，S和N）的螺环状环；RA选自H，氨基或可选取代的C¿1？至C3烷基，芳基，C1至C3烷氧基或C1至C3氨基烷基基团；R?B¿选自H，C¿1？至C3烷基或取代的C1至C3烷基；R?3¿选自H，OH，NH¿2 COR?C，或可选取代的C¿1？至C6烷基，C3至C6烯基或炔基基团；R?C¿选自H或可选取代的C¿1？至C3烷基，芳基，C1至C3烷氧基或C1至C3氨基烷基基团；Q?1¿选自S，NR?7; 或CR8R9，R5¿为可选的三取代苯环或带有1、2或3个选自O，S，SO，SO¿2？或NR?6¿的杂环的可选取代的五元或六元环；或其药学上可接受的盐，以及使用这些化合物进行避孕和治疗孕激素相关疾病的方法。
• [EN] CONTRACEPTIVE COMPOSITIONS CONTAINING QUINAZOLINONE AND BENZOXAZINE DERIVATIVES<br/>[FR] COMPOSITIONS CONTRACEPTIVES CONTENANT DE LA QUINAZOLINONE ET DES DERIVES DE BENZOXAZINE
  申请人：AMERICAN HOME PROD

  公开号：WO2000066165A1

  公开（公告）日：2000-11-09

  This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of general structure: (I) wherein: R?1 and R2¿ are H, COR?A, or NRBCORA¿, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic; or R?1 and R2¿ fuse to form 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H or alkyl; R3 is H, OH, NH¿2, COR?C or alkyl, alkenyl, or alkynyl; RC is H, alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO¿2?, alkyl, alkynyl, alkoxy, amino or aminoalkyl; R?5¿ is benzen or 5- or 6-membered heterocyclic ring; R6 is H or alkyl; G¿1? is O, NR7, or CR7R8; G2 is CO or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof. These methods may be used for contraception or treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及循环组合疗法，利用与孕激素、雌激素或两者结合使用的化合物，这些化合物是一般结构的孕激素受体拮抗剂：（I）其中：R?1和R2¿为H、COR?A或NRBCORA¿、烷基、烯基、炔基、环烷基、芳基或杂环基；或R?1和R2¿融合形成3至8个成员的螺环烷基、烯基或杂环环；RA为H或可选择的取代烷基、芳基、烷氧基或氨基烷基；RB为H或烷基；R3为H、OH、NH¿2、COR?C或烷基、烯基或炔基；RC为H、烷基、芳基、烷氧基或氨基烷基；R4为H、卤素、CN、NO¿2？、烷基、炔基、烷氧基、氨基或氨基烷基；R?5¿为苯或5-或6-成员杂环环；R6为H或烷基；G¿1？为O、NR7或CR7R8；G2为CO或CR7R8；但是当G1为O时，G2为CR7R8，且G1和G2不能同时为CR7R8；R7和R8为H或可选择的取代烷基、芳基或杂环基团；或其药学上可接受的盐。这些方法可用于避孕或治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症；多囊卵巢综合症、子宫内膜癌和腺癌、卵巢、乳腺、结肠、前列腺癌的最小化副作用或周期性月经出血。本发明的其他用途包括刺激食欲。
• [EN] QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS<br/>[FR] DERIVES DE QUINAZOLINONE ET DE BENZOXAZINE TENANT LIEU DE MODULATEURS DU RECEPTEUR DE PROGESTERONE
  申请人：AMERICAN HOME PROD

  公开号：WO2000066560A1

  公开（公告）日：2000-11-09

  This invention provides compounds which are agonists and antagonists of the progesterone receptor having general structure (I): wherein R?1 and R2¿ are independently selected from H, COR?A, or NRBCORA¿, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic moieties; or R?1 and R2¿ are fused to form: 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H, C¿1? to C3 alkyl or substituted C1 to C3 alkyl; R?3¿ is H, OH, NH¿2, COR?C or optionally substituted alkyl, alkenyl, or alkynyl; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO¿2?, or optionally substituted alkyl, alkynyl, alkoxy, amino or aminoalkyl; R?5¿ is an optionally substituted benzene or five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO¿2? or NR?6; R6¿ is H or C¿1? to C3 alkyl; G1 is O, NR7, or CR7R8; G2 is CO, CS, or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof, and methods using these compounds in mammals as agonists or antagonists of the progesterone receptor.

  本发明提供了一种具有一般结构（I）的孕激素受体激动剂和拮抗剂的化合物，其中R1和R2独立地选自H、COR A或NRB CORA，或者是可选取代的烷基、烯基、炔基、环烷基、芳基或杂环基；或者R1和R2融合形成3到8个成员的螺环烷基、烯基或杂环环；RA是H或可选取代的烷基、芳基、烷氧基或氨基烷基；RB是H、C1到C3烷基或取代的C1到C3烷基；R3是H、OH、NH2、CORC或可选取代的烷基、烯基或炔基；RC是H或可选取代的烷基、芳基、烷氧基或氨基烷基；R4是H、卤素、CN、NO2或可选取代的烷基、炔基、烷氧基、氨基或氨基烷基；R5是可选取代的苯或含有1、2或3个O、S、SO、SO2或NR6的五元或六元环；R6是H或C1到C3烷基；G1是O、NR7或CR7R8；G2是CO、CS或CR7R8；但当G1是O时，G2是CR7R8，且G1和G2不能同时为CR7R8；R7和R8是H或可选取代的烷基、芳基或杂环基；或其药学上可接受的盐，以及在哺乳动物中使用这些化合物作为孕激素受体的激动剂或拮抗剂的方法。